New Stock News: Lengke Pharmaceuticals submits application to the Hong Kong Stock Exchange. Their core product LNK01001 has the potential to become the best second-generation JAK1 inhibitor.

Zhitong Financial APP learned that, according to the disclosure of the Hong Kong Stock Exchange on November 30th, Lingke Pharmaceutical (Zhejiang) Co., Ltd. (referred to as Lingke Pharmaceutical) has submitted its application to the main board of the Hong Kong Stock Exchange, with CITIC Securities and BOC International acting as joint sponsors.